针对非囊性纤维化支气管切除症的布伦索卡提布的概况
Alexander I Geyer1, Mark L Metersky2
1Division of Pulmonary, Critical Care and Sleep Medicine, Lenox Hill Hospital, New York, NY, USA.
布伦索卡提布是一种新型的DPP1抑制剂,通过减少炎症来治疗非囊性纤维化支气管炎症,显示出有前途. 临床试验表明,它有可能在这种日益严重的呼吸道疾病中管理恶化.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 炎症研究 炎症研究
背景情况:
- 非囊性纤维化支气管炎 (NCFB) 是一种具有显著发病率的流行呼吸道疾病.
- 炎症,特别是中性粒细胞驱动的炎症,是NCFB病理生理学的核心.
- 目前的NCFB疗法具有有限的疗效,突出显示了尚未满足的医疗需求.
研究的目的:
- 审查NCFB中炎症的作用.
- 描述brensocatib的作用机制,这是一个二二基化酶1 (DPP1) 抑制剂.
- 总结关于brensocatib在NCFB患者中的疗效和安全性的临床试验数据.
主要方法:
- 对NCFB和brensocatib的现有文献的审查.
- 分析2期和3期临床试验数据,重点关注恶化率.
- 布伦索卡提布的药理特征和作用机制的概述.
主要成果:
- 布伦索卡提布显示持续抑制中性粒细胞血清蛋白酶.
- 第二阶段和第三阶段的研究表明,在用brensocatib治疗的NCFB患者中,恶化率有所降低.
- 在临床试验中,布伦索卡提布的耐受性一般很好.
结论:
- 布伦索卡提布 (Brensocatib) 是一个有前途的第一级DPP1抑制剂,用于NCFB治疗.
- 它的机制针对NCFB的关键炎症途径.
- 需要进一步评估brensocatib在现有和新兴疗法的背景下.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:35Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
Published on: April 22, 2022
相关概念视频
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Drugs for Treatment of Constipation-Predominant IBS
